SecBot SecBot
PRESS-RELEASE ·Filed Aug 26, 2026

RVMD

Revolution Medicines, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This is a landmark approval for RVMD, the first targeted RAS inhibitor for pancreatic cancer with unprecedented survival data. The stock has already appreciated significantly (market cap $45B) but the commercial opportunity is large given the high unmet need. Watch for: (1) initial prescription uptake and payer coverage in coming weeks, (2) EMA phased review timeline for EU approval, (3) expansion into NSCLC (Phase 3 registrational program ongoing), and (4) potential for label expansion into earlier lines of therapy.

DirectionBullish
Confidencehigh
Horizonweeks

daraxonrasib

▲ Bullish Named in this press release
Impact
Phase
Phase 3 (completed with positive results) / pre-NDA
Time to market
NDA submission pending; potential approval in 2L PDAC possibly by Q3 2026 per Truist analyst projection, though no PDUFA date is confirmed
Next catalyst
None dated

What to watchDaraxonrasib's Phase 3 success in 2L pancreatic cancer is already priced in after the stock surged near its 52-week high. Near-term upside hinges on formal NDA acceptance and a confirmed PDUFA date. Watch for the NDA filing announcement, which could trigger a smaller bump, but the big binary is behind us. The real long-term story is the broader pipeline (RASolute 303 in 1L PDAC, RASolve 301 in NSCLC), those future readouts are multi-year catalysts.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$215.44
T+0 close · Aug 26, 2026 · via day close
Latest settled
−7.23%
T+20 · $199.86 · next T+60 in 2d
Vs SPY
−7.46%
α at T+20
Latest observation
−8.84%
T+56 · FF3 residual α
  1. T+0 · Aug 26 $215.44entry
  2. T+1 · 3mo ago +2.65%α +2.00% · $221.15
  3. T+5 · 3mo ago −2.88%α −2.76% · $209.23
  4. T+20 · 8w ago −7.23%α −7.46% · $199.86
  5. T+57 · todayOpen
  6. T+60 · in 2d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines received FDA approval for RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior therapy. The Phase 3 RASolute 302 trial showed a 60% reduction in death risk (HR 0.40) and median OS of 13.2 months vs 6.7 months for chemotherapy. This is the first approved targeted RAS inhibitor for pancreatic cancer, a major commercial opportunity for RVMD given the high unmet need and large patient population (~55,000 annual US diagnoses).

Key Facts

  • FDA approved RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy
  • Phase 3 RASolute 302 trial showed 60% reduction in risk of death (HR 0.40; p<0.0001) vs chemotherapy
  • Median overall survival 13.2 months with RASONQUE vs 6.7 months with chemotherapy
  • Median progression-free survival 7.2 months vs 3.6 months (HR 0.49; p<0.0001)
  • First approved targeted RAS(ON) multi-selective inhibitor for pancreatic cancer
  • Once-daily oral tablet now available by prescription in the US with (ON)Path patient support program
  • Approval does not require companion diagnostic test; covers patients with or without identified RAS mutation
  • Breakthrough Therapy Designation and Orphan Drug Designation granted by FDA
  • EMA phased review ongoing; Orphan Medicinal Product designation for pancreatic cancer in EU

Financial Impact

First-in-class RAS inhibitor for ~55,000 annual US PDAC diagnoses with 80% metastatic at diagnosis; 5-year survival ~3% in metastatic setting; no prior targeted therapy existed; pricing not disclosed but represents transformative commercial opportunity for $45B market cap company

revenuemarket sharepipeline value

Risk Factors

  • Competition from other RAS inhibitors in development (e.g., Amgen's sotorasib, Mirati's adagrasib, and other RAS multi-selective programs)
  • Safety profile includes dermatologic toxicity (86%), stomatitis (57%), diarrhea (63%), and rare but serious GI perforation (0.9%) and ILD/pneumonitis (2.4%)
  • Commercial adoption may be slower than expected if physicians are cautious about new targeted therapy in a difficult-to-treat population
  • Pricing and reimbursement uncertainty; patient access programs may limit near-term revenue
  • Dependence on single product for revenue; pipeline diversification still in clinical stages

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3351615

US Market Status

Market Closed · Opens Wed (9h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 26, 2026